KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Hemasphere · 2026-Jun · PMID 42306064

Panel E质量警告待 EXE 对齐验证

EFS

Figure 3 Kaplan–Meier plots and risk tables estimating event‐free and overall survival in the CLL12 trial. (A , B) EFS (A) and OS (B) of patients from all trial arms. The comparison is carried out between patients expressing IGLV3‐21 R110 (black) and patients not expressing IGLV3‐21 light chains (blue) or expressing IGLV3‐21 G110 (green), taken as one group. (C , D) EFS (C) and OS (D) of patients from the placebo (green) and ibrutinib (blue) arms. Within each treatment arm, patients expressing IGLV3‐21 R110 (dashed lines) are compared against patients who do not express IGLV3‐21 R110 (solid lines). (E , F) EFS (E) and OS (F) of patients from the observational arm. The comparison is carried out between patients expressing IGLV3‐21 R110 (black) and patients not expressing IGLV3‐21 light chains (blue) or expressing IGLV3‐21 G110 (green), taken as one group. Hazard ratios (HR) with 95% confidence intervals and P values were calculated using the Cox proportional hazards regression model with the Wald test. Statistics for all possible pairwise comparisons in (A , B) and (E , F) are provided in Supporting Information S1: Tables S5–S8.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.91
质量通过否
预期曲线3
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证22026-07-23T16:46:10+00:00